12:30 - 12:45 OPENING CEREMONY

• About EHA/EBMT and their activities
  P Sonneveld (EHA) & N Kröger (EBMT)

12:45 - 14:15 SESSION 1: LATEST CLINICAL DATA

Chairs: H Einsele (Germany) & M Mohty (France)

• CD19 - ALL/Lymphoma
  C Roddie (United Kingdom)
• BCMA - Myeloma
  A Garfall (USA)
• CD123 - AML
  E Budde (USA)

14:15 - 15:15 SESSION 2: WHEN TO USE CAR T IN…

Chairs: P Sonneveld (The Netherlands) & I Yakoub-Agha (France)

• Acute leukemia
  M Mohty (France)
• Lymphoma
  MJ Kersten (The Netherlands)
• Multiple myeloma
  H Einsele (Germany)

15:15 - 15:45 Coffee break

15:45 - 16:30 SESSION 3: KEY NOTE LECTURE

Chairs: C Chomienne (France) & I Yakoub-Agha (France)

• Improving outcomes of therapy with CAR T cells
  S Riddell (USA)

16:30 - 17:30 SESSION 4: CAR T IN PEDIATRICS

Chairs: F Locatelli (Italy) & C Rössig (Germany)

• Academic CAR T cell trials for pediatric patients in Europe
  F Locatelli (Italy)
• Title to be announced
  A Baruchel (France)
• Real life experience in the treatment of pediatric, adolescent and young adult ALL patients using commercially available CAR T cells
  P Bader (Germany)

17:30 - 18:30 BEST ABSTRACTS & FLASH TALKS - PART I

Chairs: H Einsele (Germany) & C Chabannon (France)

• Oral 1.1 - Combining de-glycosylating agents with CAR T Cells for targeting solid tumors and reducing toxicity
  B.G. Greco (Italy)
• Oral 1.2 - Tandem autologous transplantation and combined infusion of CD19 and BCMA-specific CAR T-Cells for high risk MM: initial safety and efficacy report from a clinical pilot study
  C.C. Fu (China)
• Oral 1.3 - Attenuated membrane-proximal signaling limits the antigen sensitivity of CAR T Cells
  V. Gudipati (Austria)
• Oral 1.4 - Feasibility of point-of-care production of CD19 CAR T Cells in an automated closed-system bioreactor: report of first clinical experience
  L. Shelikhova (Russia)
• Oral Flash 1.5 - Targeting CD79b with CARs shows potent pre-clinical efficacy in mantle cell lymphoma
  M. Ormhøj (Denmark)
• Oral Flash 1.6 - NKG2D-CAR memory T cells as an Immunotherapeutic approach against pediatric acute leukemia
  L. Fernández (Spain)
• Oral Flash 1.7 - pFAR-Based CAR T Cell engineering using non-viral sleeping beauty transposition
  F. Schmitt (Germany)
• Oral Flash 1.8 - IL-1 receptor accessory protein (IL-1RAP) can be a cell-surface antigen for targeting the leukemic hematopoietic stem cells by CART-Cell immunotherapy
  F. Christophe (France)

18:30 - 20:00 Welcome reception & poster session

08:30 - 10:00 SESSION 5: PRE-CLINICAL & CLINICAL PIPELINE - PART I

Chairs: J Delgado (Spain) & U Koehl (Germany)

• New targets and technologies for CAR-T cells
  M Hudecek (Germany)
• CAR T-cell therapy for childhood solid tumours
  K Straathof (United Kingdom)
• Preclinical and clinical studies with CAR-T cells at University of North Carolina
  G Dotti (USA)
• CARs, TRUCKs and beyond: the next generation of CAR T cells
  H Abken (Germany)

10:00 - 10:45 SESSION 6: KEY NOTE LECTURE

Chairs: H Einsele (Germany) & U Koehl (Germany)

• Next Generation CAR T cells
  C June (USA)

10:45 - 11:15 Coffee break

11:15 - 12:15 SESSION 7: BEST ABSTRACTS & FLASH TALKS - PART II

Chairs: M Hudecek (Germany) & A Ruggeri (Italy)

• Oral 2.1 - From regulatory approval to reimbursement of CAR-Ts: can health technology assessment methods keep up with the fast pace of discovery in oncology?
  A. Forsythe (USA)
• Oral 2.2 - Dual targeting strategy of acute myeloid leukemia by engineered cytokine-induced killer cells coexpressing an interleukin 3 zetakine and an anti-CD33 costimulatory receptor
  V.M. Perriello (Italy)
• Oral 2.3 - CAR T cells specific for ROR1 are effective against lung and breast cancer in advanced microphysiologic 3D tumor models
  L. Wallstabe (Germany)
• Oral 2.4 - Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity
  M. Cazaux (France)
• Oral Flash 2.5 - Combinatorial targeting of multiple shared antigens by adapter CAR T cells (AdCAR-Ts) allows target cell discrimination and specific lysis based on differential expression profiles
  P. Word (Germany)
• Oral Flash 2.6 - Impact of immune impairment on infectious complications following ARI-0001 cell (A3B1:CD8:4-1BB:CD3Z CART19) treatment in patients with CD19+ relapsed / refractory malignancies: an analysis of an academic CART19
  V. Ortiz-Maldonado (Spain)
• Oral Flash 2.7 - Combinatorial systems for improved CART cell therapy against AML
  J.R. Rodriguez-Madoz (Spain)
• Oral Flash 2.8 - PiggyBac mediated T cells expressing anti CD19 CAR for a clinical trial
  N. Nishio (Japan)

12:15 - 13:00 SESSION 8: KEY NOTE LECTURE

Chairs: C Chomienne (France) & A Ruggeri (Italy)

• CAR therapy: The next wave
  M Sadelain (USA)

13:00 - 14:30 Lunch

13:45 - 14:30 SATELLITE SYMPOSIUM BY KITE/GILEAD

CAR T: TRANSFORMING OUTCOMES IN RELAPSED/REFRACTORY DLBCL

Chair: S. Le Gouill (France)

• Identifying the appropriate patient for CAR T therapy
  S Le Gouill (France)
• Management of adverse events
  M von Bergwelt (Germany)
• Bringing CAR T therapy into the discussion
  C Thieblemont (France)

14:30 - 16:00 SESSION 9: EMA & INDUSTRY PERSPECTIVE ON CAR T IN EU

Chairs: U Jäger (Austria) & G Salles (France)

• CAR-T cells - a regulatory view from the EMA Committee for Advanced Therapies
  M Schüssler-Lenz (Germany)
• Opportunities for CAR-T cells research in Horizon programs
  D Gancberg (Belgium)
• Reimbursement
  C Haag (Germany)
• Gilead
  D Tonelli (France)
• Novartis
  E Ostuni (Switzerland)
• Janssen
  M Kalos (USA)
• Celgene
  S Frankel (USA)

16:00 - 17:00 SESSION 10: CLINICAL IMPLEMENTATION & MANAGEMENT

Chairs: MJ Kersten (The Netherlands) & C Thieblemont (France)

• Würzburg experience
  M Hudecek (Germany)
• Lille experience
  I Yacoub-Agha (France)
• Milan experience
  F Ciceri (Italy)
• CART19-BE-01 trial
  J Delgado (Spain)
• RWE for CAR T evaluation
  D Schulthess (The Netherlands)

17:00 - 17:30 Coffee break

17:30 - 18:30 SESSION 11: PRE-CLINICAL & CLINICAL PIPELINE - PART II

Chairs: AA van de Loosdrecht (The Netherlands) & chair to be announced

• TEGs
  J Kuball (Germany)
• CAR-T Treatment for B-cell ALL: Experience from China
  P Lu (China)
• Non-Viral Genetic Engineering of Cytokine-Induced Killer (CIK) Cells with Chimeric Antigen Receptors (CARs) for the Targeting of Acute Myeloid Leukemia
  S Tettamanti (Italy)
• Genome edited allo-CAR T cells
  W Qasim (United Kingdom)

PARALLEL SESSIONS

08:30 - 09:45 SESSION 12: GENERAL SESSION - PART I

Chairs: AA van de Loosdrecht (The Netherlands) & R Duarte (Spain)

• CAR-T cells for non immunologists: A simple description of the technology
  M Hudecek (Germany)
• Current status of CAR-T cell development in Europe and elsewhere
  A Urbano-Ispizua (Spain)
• The supply chain for autologous CAR-T cell from a hospital perspective
  C Chabannon (France)

08:30 - 09:45 SESSION 13: NURSES SESSION - PATIENT CARE - PART I

Chairs: E Aerts (Switzerland) & J Murray (United Kingdom)

• What is driving CARs into the spotlight - The science simplified
  E Vickers (United Kingdom)
• A CAR-T for Everything - Overview of current studies and indications
  L Wood (United Kingdom)
• Patient selection and harvesting the CAR
  M Vercasson (France)

08:30 - 09:45 SESSION 14: DATA MANAGERS SESSION - DATA COLLLECTION & LTFU - PART I

Chairs: J Sierra (Spain) & P Ljungman (Sweden)

• The Cell Therapy Form in the EBMT registry
  C Ruiz de Elvira (United Kingdom)
• The EMA initiative on registries
  E McGrath (Spain)
• Specifics of LTFU for patients treated with gene / cell therapy medicinal products
  A van Biezen (The Netherlands)

09:45 - 10:15 Coffee break

PARALLEL SESSIONS

10:15 - 12:00 SESSION 15: GENERAL SESSION - PART II

Chairs: J Snowden (United Kingdom) & N Kröger (Germany)

• Issues with centers selection and qualification
  T Pagliuca (United Kingdom)
• Reimbursement
  C Haag (Germany)
• Patient perspectives
  N Bolaños (France) & B Verhoeven (The Netherlands)

10:15 - 12:00 SESSION 16: NURSES SESSION - PATIENT CARE - PART II

Chairs: E Aerts (Switzerland) & R Ellard (United Kingdom)

• Evaluation & preparation of pediatric patients for CAR T-Cell treatment
  D Hutt (Israel)
• Treatment and nursing assessment post CAR T cells in Ambulatory Care settings
  D Comerford (United Kingdom)
• The EBMT Guidelines for practice - A framework for managing Patient Care, CRS and Neurotoxicity
  R Ellard (United Kingdom) & O Stewart (United Kingdom)

10:15 – 12:00 SESSION 17: DATA MANAGERS SESSION - DATA COLLECTION & LTFU - PART II

Chairs: J Sierra (Spain) & M Labopin (France)

• PASS Studies and CAR T: Regulatory requirements
  SR Terwel (The Netherlands)
• Example on registration
  Speaker to be announced
• From Promise to MACRO and minimalized data sets
  P Ljungman (Sweden)

12:00 - 13:00 Lunch

PARALLEL SESSIONS

13:00 - 14:30 SESSION 18: GENERAL SESSION - PART I - REPEAT

Chairs: AA van de Loosdrecht (The Netherlands) & JO Bay (France)

• CAR-T cells for non immunologists: A simple description of the technology
  M Hudecek (Germany)
• Current status of CAR-T cell development in Europe and elsewhere
  A Urbano-Ispizua (Spain)
• The supply chain for autologous CAR-T cell from a hospital perspective
  C Chabannon (France)

13:00 - 14:30 SESSION 19: PHYSICIANS SESSION - PATIENT CARE - PART I

Chairs: S Izraeli (Israel) & C de Haar (The Netherlands)

• The Dutch experience for clinical implementation of CAR T cells in children and adults
  M Minnema (The Netherlands)
• Management of CRS and neurotoxicities
  M Topp (Germany)
• A quality system for centers administrating CAR T cells: The JACIE model
  E McGrath (Spain)

13:00 - 14:30 SESSION 20: CELL COLLECTION, CELL PROCESSING FACILITIES AND HOSPITAL PHARMACIES PERSONNEL - MASTERING THE SUPPLY CHAIN - PART I

Chairs: MJ Kersten (The Netherlands) & G Basak (Poland)

• Collection of autologous mononuclear cells
  H Bönig (Germany)
• Processing, QC and shipment of collected cells
  J Larghero (France)
• Point-of-care manufacturing
  J Delgado (Spain)

14:30 - 15:00 Coffee break

PARALLEL SESSIONS

15:00 - 16:30 SESSION 21: GENERAL SESSION - PART II – REPEAT

Chairs: J Murray (United Kingdom) & S Montoto (Italy)

• Issues with centers selection and qualification
  T Pagliuca (United Kingdom)
• Patient perspectives
  N Bolaños (France) & B Verhoeven (The Netherlands)

15:00 - 16:30 SESSION 22: PHYSICIANS SESSION - PATIENT CARE - PART II

Chairs: S Izraeli (Israel) & A Mackensen (Germany)

• Evaluation of disease response
  A Nagler (Israel)
• Is this the end? The need for consolidation? Bridge to transplantation? CAR-T cells in treatment strategies
  S Mielke (Sweden)
• The EBMT Registry: Fulfilling the needs of multiple stakeholders
  N Kröger (Germany)

15:00 - 16:30 SESSION 23: CELL COLLECTION, CELL PROCESSING FACILITIES AND
HOSPITAL PHARMACIES PERSONNEL - MASTERING THE SUPPLY CHAIN - PART II

Chairs: N Worel (Austria) & W Herr (Germany)

• Role of the pharmacist in reception, storage and delivery of CAR-T Cells. Transfer to the clinical ward and delivery of the gene therapy medicinal product
  C de Haar (The Netherlands)
• Techniques for thawing cryopreserved CAR-T Cells
  B Mfarrej (France)
• "Out-of-specification" products
  A Bersenyev (USA)

16:30 - 16:45 CLOSING REMARKS

• H Einsele (Germany) & C Chabannon (France)